<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322019</url>
  </required_header>
  <id_info>
    <org_study_id>PO20032</org_study_id>
    <nct_id>NCT04322019</nct_id>
  </id_info>
  <brief_title>Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study</brief_title>
  <acronym>AMIDIAL-ICU</acronym>
  <official_title>Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amikacin is the aminoglycoside of choice for treatment of severe infections in intensive
      care. An achievement of its objectives in pharmacokinetics and pharmacodynamics is difficult
      in intensive care patients because of modification of their volume of distribution and renal
      clearance. Acute renal failure requiring renal replacement therapy is frequent in intensive
      care. Extrarenal purification modalities (continuous versus intermittent, type of dialysis
      membrane), which can influence amikacin clearance, are multiple and teams dependent.
      Guidelines of good practice for Amikacin in intensive care patients do not exist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to describe strategies of prescription and monitoring of Amikacin in
      intensive care patients on renal replacement therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">May 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of maximum concentration observed</measure>
    <time_frame>Day 0</time_frame>
    <description>Monitoring of Amikacin treatment using measurement of maximum concentration observed performed or not</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Amikacin Treatment</condition>
  <arm_group>
    <arm_group_label>&quot;Amikacin treatment&quot; group</arm_group_label>
    <description>Intensive care patients on renal replacement therapy with Amikacin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data record</intervention_name>
    <description>Data record</description>
    <arm_group_label>&quot;Amikacin treatment&quot; group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Intensive care patients on renal replacement therapy with Amikacin treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        inclusion criteria :

          -  patients in intensive care

          -  patients on extrarenal replacement

          -  patients with Amikacin treatment

          -  patients accepting to participate in the study

        exclusion criteria :

          -  patients less than 18 years old

          -  pregnant women

          -  patients with Amikacin treatment in the previous 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincent DUPONT</last_name>
    <phone>0326788819</phone>
    <email>vdupont@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damien JOLLY</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent DUPONT</last_name>
      <phone>0326788819</phone>
      <phone_ext>0033</phone_ext>
      <email>vdupont@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amikacin</keyword>
  <keyword>intensive care</keyword>
  <keyword>renal replacement therapy</keyword>
  <keyword>prescription strategy,</keyword>
  <keyword>monitoring strategy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

